Guardant Health, Inc. Common Stock

Day range

$168.73 – $175.08

Open

$170.10

Prev close

$169.08

Volume

1.1M

Market cap

$22.69B

Shares out

134.2M

P/E

—

P/S

19.18

P/B

-101.81

P/FCF

—

ROE

203.5%

ROA

-23.7%

Debt/Equity

-6.74

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsJun 18, 2026

  All of the nominees for director listed in Proposal 1 in the Company's Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement"), were elected to serve on the Company's board of directors by the following vote: Ian Clark 70,526,891 votes for, 37,916,548 withheld; Manuel Hidalgo Medina 81,925,123 votes for, 26,518,316 withheld.

• Executive officer departureApr 27, 2026

  On April 27, 2026, Guardant Health, Inc. (the "Company") announced the resignation of Craig Eagle, M.D., the Company's Chief Medical Officer, to be effective as of May 8, 2026.

• Preliminary resultsJan 12, 2026

  On January 11, 2026, Guardant Health, Inc. (the "Company") announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025.

• Public offeringNov 7, 2025

  On November 4, 2025, Guardant Health, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the public offering of 3,833,332 shares (the "Shares") of the Company's common stock, par value $0.00001 per share (the "common stock"), at a public offering price of $90.00 per share (the "Common Stock Offering").

• Equity compensation grantSep 15, 2025

  Secretary Azar will receive the standard compensation paid by the Company to all of its non-employee directors under the Company's Amended Non-Employee Director Compensation Program (the "Program"). Pursuant to the Program, Secretary Azar will receive a stock option award and restricted stock unit award, each with a value of $362,500 (collectively, the "Initial Awards"). Each of the Initial Awards will vest with respect to one-fourth (1/4th) of the shares subject thereto on the first anniversary of Secretary Azar's appointment to the Board, and as to the remaining three-fourths (3/4ths) of the shares subject thereto on each monthly anniversary of Secretary Azar's appointment to the Board during the three-year period thereafter, subject to continued service through the applicable vesting date.

Days to cover

6.2

Short interest

11.92M

Avg volume

1.92M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Natera Partners With TransCode to Advance Colorectal Cancer Trial
  positiveZacks Investment Research· Oct 21, 2026
• Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
  neutralZacks Investment Research· Oct 19, 2026
• These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
  positiveZacks Investment Research· Oct 15, 2026
• AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
  positiveZacks Investment Research· Sep 7, 2026
• Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Aug 27, 2026